← BackBrowse analysis archive →
GSK lung cancer drug shows 61% response rate in early global trial
Proactive Investors · 25d ago · Sentiment +0.72
Read original ↗Impact scope
2 industries
direct 1·2nd-order 4
Top gainer
🔒
Top loser
🔒
Impact chainNews → industry → company, ranked top-down by impact
Pro only
Impact chains, crowding, market view and insider signals — try Pro free for 7 days when you sign up.
Start my free trial